Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Amphastar Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Amphastar Pharmaceuticals, Inc.

AMPH

Amphastar Pharmaceuticals, Inc.

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. develops, manufactures, markets, and sells complex generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, along with insulin active pharmaceutical ingredients (APIs). The company targets high-barrier markets such as injectables and inhalation therapies, serving hospitals, clinics, and pharmacies primarily in the U.S. Amphastar’s vertically integrated model combines advanced R&D, manufacturing, and regulatory expertise to deliver technically challenging drugs with limited competition and strong supply chain control.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Amphastar Pharmaceuticals, Inc.

1
1
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals Reports Slight Revenue Increase but Significant Profit Decline in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals Reports Decrease in Net Revenues to $719.9 Million for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals Reports Q3 2025 Financial Results with Increased Revenues and Declining Net Income

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals Reports 4% Revenue Decline in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals Reports Q1 2025 Financial Results with $170.5M Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals Reports 14% Revenue Growth to $732M in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals Reports 6% Revenue Growth, Net Income Decline in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments